Novo Nordisk partners with Vivtex in up to $2.1 billion deal for oral obesity drugs | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, February 4, 2026. REUTERS/Tom Little/File Photo [Purchase Licensing Rights, opens new tab]- Companies[Novo Nordisk A/S]Follow[Vivtex Corporation]FollowFeb 25 (Reuters) - Danish drugma ...

Core Viewpoint - The phase 2 trial results of UBT251, a triple agonist for GLP-1, GIP, and glucagon receptors, indicate significant weight loss and safety in Chinese patients with obesity or overweight, marking a milestone for United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S in their collaboration [1][3][5]. Group 1: Trial Results - UBT251 demonstrated a mean weight loss of 19.7% (-17.5 kg) in the treatment group compared to 2.0% (-1.6 kg) in the placebo group after 24 weeks [3][9]. - Statistically significant improvements were observed in secondary endpoints, including waist circumference, blood glucose, blood pressure, and lipids [4][9]. - The trial involved 205 Chinese patients with a baseline mean body weight of 92.2 kg and a mean BMI of 33.1 kg/m² [7]. Group 2: Development and Future Plans - United Biotechnology plans to initiate a phase 3 trial in Chinese patients based on the phase 2 results [6]. - Novo Nordisk has started a global phase 1b/2a trial with UBT251, expecting topline data in 2027, and plans to initiate a phase 2 trial for type 2 diabetes in the second half of 2026 [5][6]. Group 3: Company Background - TUL is a leading integrated pharmaceutical company in China, focusing on the research and development of pharmaceuticals, with a strong presence in nearly 80 countries [12]. - Novo Nordisk is a global healthcare leader founded in 1923, dedicated to combating chronic diseases, particularly diabetes, and operates in around 170 countries [13].

Core Viewpoint - The conference call is hosted by Novo Nordisk, indicating a focus on investor relations and company performance updates [1] Group 1 - The call is being recorded, suggesting that the information shared will be available for future reference [1] - Michael Novod, the Head of Investor Relations, is the first speaker, highlighting the importance of investor communication in the company's strategy [1]

Core Viewpoint - Novo Nordisk's shares fell over 15% following a trial setback for its obesity drug CagriSema, which underperformed compared to Eli Lilly's tirzepatide, erasing gains from the launch of Wegovy [1][2]. Group 1: Company Performance - Novo Nordisk's market valuation dropped from over $600 billion in 2024 to a loss of approximately $400 billion, returning shares to levels last seen before the launch of Wegovy [2]. - The company's shares are now at their lowest since June 2021, indicating a significant decline in investor confidence [2]. Group 2: Market Competition - Analysts from J.P. Morgan indicated that the trial miss for CagriSema represents a major setback that could limit its demand and long-term sales potential, impacting Novo's ability to regain market share in the growing obesity treatment sector [2][3]. - The competition in obesity treatments is intensifying, with market demand increasingly favoring drugs that provide the most substantial weight-loss results [3]. Group 3: Stock Market Reaction - Novo Nordisk was one of the worst performers on the European benchmark STOXX 600 index, while shares of its competitor Eli Lilly rose by about 4% in U.S. premarket trading [4].

Economic Data - The core PCE price index rose by +0.4% month-over-month and +3.0% year-over-year in December, exceeding expectations of +0.3% and +2.9% respectively [1] - The U.S. economy grew at a +1.4% annualized rate in Q4, which was below the expected +2.8% [1] - Personal spending in December increased by +0.4% month-over-month, aligning with expectations, while personal income grew by +0.3% month-over-month, also in line with expectations [1] - The University of Michigan's consumer sentiment index for February was revised down to 56.6, weaker than the expected 56.9 [1] Stock Market Performance - Wall Street's major equity averages closed higher, with Alphabet (GOOGL) leading the Nasdaq 100 with a gain of over +4% and Amazon.com (AMZN) rising more than +2% in the Dow [2] - Chip stocks performed well, with Lam Research (LRCX) up over +3% and Analog Devices (ADI) advancing more than +2% [2] - Corning (GLW) surged over +7% after UBS raised its price target from $125 to $160 [2] - Cybersecurity stocks faced declines, with Cloudflare (NET) down more than -8% and CrowdStrike Holdings (CRWD) sliding over -7% [2] Upcoming Earnings Reports - Nvidia is set to report its fourth-quarter and fiscal-year results, with expectations that it will beat Wall Street's forecasts [3][7] - Other notable companies releasing quarterly results include Home Depot (HD), The TJX Companies (TJX), Lowe's (LOW), Salesforce (CRM), Intuit (INTU), Dell Technologies (DELL), and CoreWeave (CRWV) [7] Federal Reserve Insights - Atlanta Fed President Raphael Bostic indicated that maintaining mildly restrictive rates is prudent to bring inflation back to the 2% target [6] - Dallas Fed President Lorie Logan expressed cautious optimism regarding the current monetary policy stance [6] - U.S. rate futures indicate a 95.9% chance of no rate change and a 4.1% chance of a 25 basis point rate cut at the March Fed meeting [6] Trade Policy Developments - President Trump announced an increase in global tariffs from 10% to 15%, following a Supreme Court ruling [4] - The new tariffs are permitted to remain in effect for 150 days under Section 122 of the 1974 Trade Act [4] - Uncertainty regarding U.S. trade policy is contributing to market volatility, compounded by concerns over AI disruption and U.S.-Iran tensions [4] International Market Reactions - The Euro Stoxx 50 Index fell by -0.21% amid uncertainty over U.S. trade policy, with technology and industrial stocks underperforming [12] - German business morale improved more than expected, indicating signs of recovery in the German economy [12] - Italy's annual inflation rate eased to 1.0% in January, as confirmed by ISTAT [12]

Core Insights - vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral treatments for diabetes and other diseases, with key programs including TTP399 for type 1 diabetes and HPP737 for inflammatory diseases and psoriasis [1] Price Target and Analyst Sentiment - The consensus price target for VTVT has increased from $51.33 to $53.50, indicating growing optimism among analysts regarding the company's prospects [2][6] - The recent upgrade to a Zacks Rank 2 (Buy) reflects increased confidence in the company's earnings potential [2][6] Clinical Advancements - Advancements in clinical trials for TTP399 and HPP737 are influencing the positive outlook for VTVT, contributing to the increase in the consensus price target [3][6] - The potential for successful outcomes in these trials is a key factor driving analyst optimism [3] Strategic Partnerships - Strategic partnerships with organizations like Novo Nordisk A/S and JDRF International may enhance vTv's market position and growth prospects [4] - These collaborations provide additional resources and expertise, contributing to the positive sentiment reflected in the consensus price target and Zacks Rank upgrade [4] Market Performance and Investor Interest - The overall performance of the biopharmaceutical sector and investor interest in diabetes and inflammatory disease treatments could impact VTVT's stock target price [5] - Wall Street analysts indicate a potential upside of 25.2%, suggesting a favorable outlook for the stock [5]

Group 1 - Novo Nordisk has nominated Jan van de Winkel and Ramona Sequeira to its board of directors, marking the first additions since a significant management shake-up in 2025 [1] - The company replaced its CEO and overhauled the board, appointing Lars Rebien Sorensen as board chairman, who also chairs the Novo Nordisk Foundation, consolidating power in a dual role [1] - Jan van de Winkel is the co-founder and CEO of Genmab, while Ramona Sequeira previously served as President of the Global Portfolio Division at Takeda Pharmaceutical Company Limited from 2022 to 2025 [1]

Core Viewpoint - Veru Inc. is advancing its clinical programs for innovative treatments targeting cardiometabolic and inflammatory diseases, with a focus on the upcoming presentation at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [1] Company Overview - Veru Inc. is a late clinical stage biopharmaceutical company dedicated to developing innovative medicines for cardiometabolic and inflammatory diseases [3] - The company's drug development pipeline includes two late-stage novel small molecules: enobosarm and sabizabulin [3] Enobosarm Obesity Program - Enobosarm is being developed as a next-generation drug to enhance weight reduction when combined with GLP-1 RA drugs, aiming for more selective fat loss while preserving lean mass [4] - The Phase 2b QUALITY clinical study demonstrated that enobosarm, when used with semaglutide, led to greater fat loss while preserving lean mass and physical function in older patients [4] - The study involved 168 older patients (≥60 years) and showed that while weight loss was similar across treatment groups, the preservation of lean mass is expected to lead to increased energy expenditure and further weight reduction in longer studies [4] Planned Phase 2b PLATEAU Clinical Study - The upcoming Phase 2b PLATEAU clinical trial will evaluate the effects of enobosarm 3 mg on various health metrics in approximately 200 older patients (age ≥ 65) with obesity [5] - The primary efficacy endpoint is the percent change in total body weight at 68 weeks, with an interim analysis planned at 34 weeks [5] - The study aims to assess the ability of enobosarm to overcome weight loss plateaus in patients receiving GLP-1 RA treatment, with a focus on preserving muscle mass and physical function [6]

Core Viewpoint - The European Commission has approved a higher dose of Novo Nordisk's weight-loss drug Wegovy, indicating a significant development for the company in the obesity treatment market [1]. Company Summary - Novo Nordisk's Wegovy has received approval for a higher dosage, which may enhance its market competitiveness and address varying patient needs [1]. Industry Summary - The approval of a higher dose of Wegovy reflects ongoing advancements in the pharmaceutical industry, particularly in the area of obesity treatment, which is gaining increasing attention due to rising obesity rates globally [1].

Core Viewpoint - Hedge funds have significantly increased their short positions against Hims & Hers Health, coinciding with the company's recent challenges related to its weight-loss pill and legal issues with Novo Nordisk [1]. Group 1: Hedge Fund Activity - Hedge fund bets against Hims & Hers Health reached their highest level in at least a year in January, with nearly 65% of available Hims stock loaned out for short selling, the highest since October 2025 [1]. - Short interest in Hims stock hit a record high on February 12, indicating a strong bearish sentiment among investors [1]. Group 2: Company Developments - Hims & Hers Health withdrew its low-cost weight-loss pill under scrutiny from the U.S. Food and Drug Administration (FDA) and faced lawsuits from Novo Nordisk, resulting in a 33% drop in its share price within a week [1]. - The company unveiled a compounded version of Novo Nordisk's Wegovy weight-loss pill on February 5 but retracted it two days later after the FDA's warning against "illegal copycat drugs" [1]. Group 3: Market Implications - The dissolution of the partnership between Hims and Novo Nordisk has led to increased scrutiny and volatility in Hims' stock, prompting hedge funds to take short positions [1]. - Analysts suggest that without access to a branded weight-loss drug, Hims may struggle to compete in the weight-loss market [1].